These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 27836633)

  • 1. Evaluation of automated time-lapse microscopy for assessment of in vitro activity of antibiotics.
    Ungphakorn W; Malmberg C; Lagerbäck P; Cars O; Nielsen EI; Tängdén T
    J Microbiol Methods; 2017 Jan; 132():69-75. PubMed ID: 27836633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Automated time-lapse microscopy a novel method for screening of antibiotic combination effects against multidrug-resistant Gram-negative bacteria.
    Ungphakorn W; Lagerbäck P; Nielsen EI; Tängdén T
    Clin Microbiol Infect; 2018 Jul; 24(7):778.e7-778.e14. PubMed ID: 29108951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of early combination effects of colistin and meropenem against Pseudomonas aeruginosa and Acinetobacter baumannii in dynamic time-kill experiments.
    Tängdén T; Karvanen M; Friberg LE; Odenholt I; Cars O
    Infect Dis (Lond); 2017 Jul; 49(7):521-527. PubMed ID: 28264618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamic interaction of colistin and meropenem on a WT and a resistant strain of Pseudomonas aeruginosa as quantified in a PK/PD model.
    Mohamed AF; Kristoffersson AN; Karvanen M; Nielsen EI; Cars O; Friberg LE
    J Antimicrob Chemother; 2016 May; 71(5):1279-90. PubMed ID: 26850719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of the antiseptic polyhexanide against gram-negative bacteria.
    Fabry WH; Kock HJ; Vahlensieck W
    Microb Drug Resist; 2014 Apr; 20(2):138-43. PubMed ID: 24192397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pharmacokinetic-pharmacodynamic model characterizing the emergence of resistant Escherichia coli subpopulations during ertapenem exposure.
    Ungphakorn W; Tängdén T; Sandegren L; Nielsen EI
    J Antimicrob Chemother; 2016 Sep; 71(9):2521-33. PubMed ID: 27330073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences in suppression of regrowth and resistance despite similar initial bacterial killing for meropenem and piperacillin/tazobactam against Pseudomonas aeruginosa and Escherichia coli.
    Bergen PJ; Bulitta JB; Sime FB; Lipman J; McGregor MJ; Millen N; Paterson DL; Kirkpatrick CMJ; Roberts JA; Landersdorfer CB
    Diagn Microbiol Infect Dis; 2018 May; 91(1):69-76. PubMed ID: 29395712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting mutant selection in competition experiments with ciprofloxacin-exposed Escherichia coli.
    Khan DD; Lagerbäck P; Malmberg C; Kristoffersson AN; Wistrand-Yuen E; Sha C; Cars O; Andersson DI; Hughes D; Nielsen EI; Friberg LE
    Int J Antimicrob Agents; 2018 Mar; 51(3):399-406. PubMed ID: 29127049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of Different Peritoneal Dialysis Fluids on the In Vitro Activity of Cefepime, Ciprofloxacin, Ertapenem, Meropenem and Tobramycin Against Escherichia Coli.
    Kussmann M; Schuster L; Wrenger S; Pichler P; Reznicek G; Burgmann H; Poeppl W; Zeitlinger M; Wiesholzer M
    Perit Dial Int; 2016 11-12; 36(6):662-668. PubMed ID: 27680756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Antibiotic Combinations against Multidrug-Resistant Pseudomonas aeruginosa in Automated Time-Lapse Microscopy and Static Time-Kill Experiments.
    Olsson A; Wistrand-Yuen P; Nielsen EI; Friberg LE; Sandegren L; Lagerbäck P; Tängdén T
    Antimicrob Agents Chemother; 2020 May; 64(6):. PubMed ID: 32179531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
    DeRyke CA; Banevicius MA; Fan HW; Nicolau DP
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1481-6. PubMed ID: 17283197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of antibacterial activities of colistin, rifampicin and meropenem combinations against NDM-1-producing Klebsiella pneumoniae in 24 h in vitro time-kill experiments.
    Lagerbäck P; Khine WW; Giske CG; Tängdén T
    J Antimicrob Chemother; 2016 Aug; 71(8):2321-5. PubMed ID: 27334665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Control-related effective regrowth time and post-antibiotic effect of meropenem on gram-negative bacteria studied by bioluminescence and viable counts.
    Hanberger H; Svensson E; Nilsson LE; Nilsson M
    J Antimicrob Chemother; 1995 May; 35(5):585-92. PubMed ID: 7592171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamic evaluation of the intracellular activity of antibiotics towards Pseudomonas aeruginosa PAO1 in a model of THP-1 human monocytes.
    Buyck JM; Tulkens PM; Van Bambeke F
    Antimicrob Agents Chemother; 2013 May; 57(5):2310-8. PubMed ID: 23478951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pharmacokinetic-pharmacodynamic (PKPD) model based on in vitro time-kill data predicts the in vivo PK/PD index of colistin.
    Khan DD; Friberg LE; Nielsen EI
    J Antimicrob Chemother; 2016 Jul; 71(7):1881-4. PubMed ID: 26983860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro susceptibility pattern of cephalosporin-resistant Gram-negative bacteria.
    Punpanich W; Tantichattanon W; Wongwatcharapaiboon S; Treeratweeraphong V
    J Med Assoc Thai; 2008 Oct; 91 Suppl 3():S21-7. PubMed ID: 19255989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro synergism of beta-lactams with ciprofloxacin and moxifloxacin against genetically distinct multidrug-resistant isolates of Pseudomonas aeruginosa.
    Kanellakopoulou K; Sarafis P; Galani I; Giamarellou H; Giamarellos-Bourboulis EJ
    Int J Antimicrob Agents; 2008 Jul; 32(1):33-9. PubMed ID: 18538547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potentialization of β-lactams with colistin: in case of extended spectrum β-lactamase producing Escherichia coli strains isolated from children with urinary infections.
    Al Atya AK; Drider-Hadiouche K; Vachee A; Drider D
    Res Microbiol; 2016 Apr; 167(3):215-21. PubMed ID: 26723273
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Goodlet KJ; Nicolau DP; Nailor MD
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determining β-lactam exposure threshold to suppress resistance development in Gram-negative bacteria.
    Tam VH; Chang KT; Zhou J; Ledesma KR; Phe K; Gao S; Van Bambeke F; Sánchez-Díaz AM; Zamorano L; Oliver A; Cantón R
    J Antimicrob Chemother; 2017 May; 72(5):1421-1428. PubMed ID: 28158470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.